These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22313108)

  • 1. Commentary on Higashi & Barendregt (2012): Smoking cessation therapies in Vietnam.
    Pollack HA
    Addiction; 2012 Mar; 107(3):671-2. PubMed ID: 22313108
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic cigarettes for smoking cessation.
    Hagstrom K; Gannon D; Sobieraj D
    Conn Med; 2014 Aug; 78(7):435-9. PubMed ID: 25195313
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
    Jiménez-Ruiz CA; Solano-Reina S; Signes-Costa J; de Higes-Martinez E; Granda-Orive JI; Lorza-Blasco JJ; Riesco-Miranda JA; Altet-Gomez N; Barrueco M; Oyagüez I; Rejas J;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2027-36. PubMed ID: 26451100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany.
    Aumann I; Treskova M; Hagemann N; von der Schulenburg JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):441-452. PubMed ID: 27021824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Nau JY
    Rev Med Suisse; 2017 May; 13(563):1070-1071. PubMed ID: 28636304
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentary on Etter & Bullen (2011): could E-cigs become the ultimate nicotine maintenance device?
    Foulds J; Veldheer S
    Addiction; 2011 Nov; 106(11):2029-30. PubMed ID: 21978314
    [No Abstract]   [Full Text] [Related]  

  • 10. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M; Raymond V; Paradis PE
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tobacco control: where are we?].
    Paci E
    Epidemiol Prev; 2011; 35(3-4):174. PubMed ID: 21914912
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary on Ward et al. (2013): failure to find a treatment effect for NRT in a low-income country - implications.
    Lando H
    Addiction; 2013 Feb; 108(2):404-5. PubMed ID: 23331883
    [No Abstract]   [Full Text] [Related]  

  • 14. An intervention to reduce the number of convenience stores selling tobacco: feasibility study.
    Paynter J; Glover M; Bullen C; Sonia D
    Tob Control; 2016 May; 25(3):319-24. PubMed ID: 25873646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population impact of reimbursement for smoking cessation: a natural experiment in The Netherlands.
    Willemsen MC; Segaar D; van Schayck OC
    Addiction; 2013 Mar; 108(3):602-4. PubMed ID: 22994396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-level factors influencing tobacco cessation quitline spending in 2008.
    Beyer EJ; Keller PA; Bailey LA; Baker TB; Fiore MC
    Prev Med; 2010 Aug; 51(2):191-2. PubMed ID: 20478330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco use: the impact of prices.
    Leverett M; Ashe M; Gerard S; Jenson J; Woollery T
    J Law Med Ethics; 2002; 30(3 Suppl):88-95. PubMed ID: 12508509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical and pharmacological direct costs of a 9-week smoking cessation programme.
    Wasserfallen JB; Digon P; Cornuz J
    Eur J Prev Cardiol; 2012 Jun; 19(3):565-70. PubMed ID: 21450562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese health goals go up in smoke.
    Watts J
    Lancet; 2000 Jun; 355(9222):2227. PubMed ID: 10881905
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation.
    Igarashi A; Goto R; Suwa K; Yoshikawa R; Ward AJ; Moller J
    Appl Health Econ Health Policy; 2016 Feb; 14(1):77-87. PubMed ID: 26597111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.